unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), and unresectable or advanced hepatocellular carcinoma (HCC) 1. This dual ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment of adult and pediatric ...
Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...
The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult and pediatric patients with colorectal cancer. The Food and Drug ...
FDA approves Opdivo and Yervoy for unresectable or metastatic MSI-H/dMMR colorectal cancer in patients 12 and older. Opdivo's accelerated approval for single-agent use in MSI-H/dMMR metastatic CRC is ...
Based on the Phase 3 CheckMate-9DW trial, Opdivo plus Yervoy demonstrated a statistically significant overall survival benefit compared to investigator’s choice of lenvatinib or sorafenib1 In the ...
On Friday, the European Commission (EC) approved Bristol Myers Squibb & Co’s (NYSE:BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab) for the first-line treatment of adult patients with unresectable or ...
Different parts of Medicare can provide coverage for cancer treatments, including Opdivo. The coverage will depend on various factors, such as the phase of treatment and where a person receives ...
LUNGevity Foundation, the nation's leading lung cancer nonprofit, applauds the Food and Drug Administration's (FDA) approval of Bristol Myers Squibb's new immunotherapy drug Opdivo (nivolumab). Opdivo ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback